Gardasil, Other New Products Spur Strong Vaccine Sales in 2007

Tuesday, April 8, 2008 General News J E 4
NEW YORK, April 7, 2008 Stronger than anticipated revenuesfor flu vaccines, and the surprising commercial success of Merck's Gardasilfor HPV, which causes most cervical cancers, has led to a healthy $16.3billion in vaccine sales in 2007. This represents an increase of 38% over 2006sales of $11.7 billion, according to Vaccines 2008: World Market Analysis, KeyPlayers, and Critical Trends in a Fast-Changing Industry, a new marketresearch study and reforecast of the vaccine market from Kalorama Information.

According to the report, new products approved in recent years, inparticular Gardasil, but also RotaTeq, Pentacel, Zostavax and FluMist, are nowhaving an impact on the market. These new products, combined with a continuedemphasis on flu vaccines in the U.S. healthcare system, have created a healthyenvironment for vaccine products.

Five major players -- Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Wyethand Novartis -- dominate vaccine sales. At these companies, as well as smallerproducers, Kalorama Information has found increased interest in vaccines, anda willingness to look at products for conditions not historically addressedwith vaccines, including diabetes, cancer and smoking cessation. Given thistrend and strong sales, Kalorama Information expects vaccine sales to morethan double in five years.

"You might call it a 'Gardasil Effect'," says Bruce Carlson, publisher ofKalorama Information. "R&D departments are more confident about investing ina vaccine product now than in the past because a strong marketing precedenthas been established. Expect to see new vaccine products, and perhaps newcompanies in the market."

Kalorama Information's new report Vaccines 2008: World Market Analysis,Key Players, and Critical Trends in a Fast-Changing Industry reforecasts themarket for this highly profitable drug segment and addresses the dramaticchanges taking place. The report covers current world revenues and forecaststhrough 2013 for pediatric and adult vaccines, and provides pipeline analysisand company profiles. The report can be purchased directly from KaloramaInformation by visiting

About Kalorama Information

Kalorama Information supplies the latest in independent market research inthe life sciences, as well as a full range of custom research services.Kalorama routinely assists media with healthcare topics, and can provideexperts to speak about markets in the life sciences industry. For moreinformation, contact Andrea Hiller at 212-807-2673, or visit

SOURCE Kalorama Information


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
New Medicare Equipment Bidding Program for Riversi...
Dr. Ronald E. Cape to Retire from EntreMed Board o...